Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'
- PMID: 19140113
- PMCID: PMC4510047
- DOI: 10.1002/sim.3503
Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'
Abstract
In replying to Andrew Dunning’s helpful letter, we endeavor to clarify the value of incorporating baseline participant predictors of the potential surrogate endpoint and of the clinical endpoint into the evaluation of a surrogate endpoint. Such baseline predictors are useful for the evaluation of surrogates defined within each of the statistical and principal surrogate frameworks, which are complementary.
Comment on
-
Comment on 'Evaluating a surrogate endpoint at three levels, with application to vaccine development' by Peter B. Gilbert, Li Qin and Steven G. Self, Statistics in Medicine, DOI: 10.1002/sim.3122.Stat Med. 2008 Dec 20;27(29):6268-70. doi: 10.1002/sim.3425. Stat Med. 2008. PMID: 18767203 No abstract available.
References
-
- Sadoff JC, Wittes J. Correlates, surrogates, and vaccines. The Journal of Infectious Diseases. 2007;196:1279–1281. - PubMed
-
- Qin L, Gilbert PB, Corey L, McElrath J, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. The Journal of Infectious Diseases. 2007;196:1304–1312. - PubMed
-
- Salk JE, Menke WJ, Jr, Francis T., Jr A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. American Journal of Hygiene. 1943;42:57–93.
-
- Pearl J. Causality: Models, Reasoning, and Inference. Cambridge University Press; 2000.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources